Production (Stage)
Eledon Pharmaceuticals, Inc.
ELDN
$2.87
-$0.13-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.05M | -36.18M | -21.67M | -108.54M | -129.40M |
| Total Depreciation and Amortization | 264.00K | 264.00K | 270.00K | 285.00K | 282.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -42.50M | -20.06M | -25.56M | 70.87M | 94.80M |
| Change in Net Operating Assets | 6.69M | 8.71M | 9.54M | -508.00K | -4.03M |
| Cash from Operations | -54.59M | -47.27M | -37.42M | -37.90M | -38.34M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -76.21M | -70.31M | -12.86M | -25.08M | -35.50M |
| Cash from Investing | -76.21M | -70.31M | -12.86M | -25.08M | -35.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 133.64M | 133.52M | 53.36M | 48.07M | 33.02M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 133.64M | 133.52M | 53.36M | 48.07M | 33.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.84M | 15.94M | 3.08M | -14.91M | -40.83M |